In 2017 we published stories about new findings in cancer risk factors, prevention, treatment, and survivorship issues.
Reparixin oral tablets are being tested as a CSC targeting agent in participants with metastatic non- human epidermal growth factor receptor (HER2)-amplified breast cancer.
An open label phase Ib clinical study (REP0111) is ongoing (enrollment completed) in five U. sites, under IND # 112502, to test safety, tolerability, pharmacokinetics and detect early signs of antitumor activity of increasing doses of reparixin oral tablets in combination with a fixed dose of weekly paclitaxel.
This study is being conducted to confirm the performance of the Archimedes System in participants who are scheduled for standard bronchoscopy to diagnose highly suspicious lung cancer or metastatic disease.
Navigation to and sampling of the participant's lung cancer tumor is conducted.
Lenalidomide is an immunomodulatory agent with direct and immune-mediated mechanisms of action, as well as clinical activity in NHL.
Recent studies in frontline and relapsed/refractory NHL show high activity for lenalidomide plus rituximab, supporting further study of this combination.This is an open-label, single-arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high-grade serous, high-grade endometroid or clear cell ovarian, fallopian tube or primary peritoneal carcinoma patients who have received at least three prior lines of chemotherapy and who do not carry deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutations.This is an open-label, multi-center, randomized, phase III study designed to compare the efficacy and safety of AM0010 in combination with FOLFOX versus FOLFOX alone in patients with metastatic adenocarcinoma of the pancreas who have progressed on one prior gemcitabine containing regimen.This is a multi-center, open-label, first-in-human phase I study evaluating the anti-TIM-3 (T cell immunoglobulin and mucin containing protein-3) antibody TSR-022, as a monotherapy and in combination with an anti-PD-1 antibody, in patients with advanced solid tumors who have limited available treatment options.Follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma are distinct histologic types of B-cell non-Hodgkin lymphoma (NHL).Subjects in part II will be randomized in a 2:2:1 fashion to one of three treatment groups: (A) irinotecan; (B) dinutuximab plus irinotecan; or (C) topotecan.